Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 0.63 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.57 |
| ▸ | POLA1 | P09884 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18251 | 0.87 | PNP (0.62) | XDH | |
| SCHEMBL1394088 | 0.86 | PNP (0.61) | XDH | |
| SCHEMBL5935074 | 0.85 | XDH (0.78) | XDHPOLA1 | |
| Cyanide SCHEMBL2694132 | 0.84 | PNP (0.58) | XDHMAPK1 | |
| SCHEMBL25398222 | 0.81 | GDA (0.58) | POLA1 | |
| Monoethanolamine SCHEMBL27179191 | 0.80 | PNP (0.57) | XDH | |
| SCHEMBL667798 | 0.80 | XDH (0.84) | XDHPOLA1 | |
| SCHEMBL9806979 | 0.80 | XDH (0.71) | XDH | |
| SCHEMBL6751934 | 0.80 | XDH (0.71) | XDH | |
| SCHEMBL441799 | 0.80 | XDH (0.71) | XDHPOLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2992883-B1 | PHARMACEUTICAL USE OF HEXAHYDRO-DIBENZO[A,G]QUINOLIZINE COMPOUNDS | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2024-04-24 | — | — | EP | disclosed |
| US-9737517-B2 | Pharmaceutical use of hexahydro-dibenzo[a,g]quinolizine compounds | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-08-22 | — | — | US | disclosed |
| US-20160193195-A1 | PHARMACEUTICAL USE OF HEXAHYDRO-DIBENZO[A,G]QUINOLIZINE COMPOUNDS | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-07-07 | — | — | US | disclosed |
| EP-2992883-A1 | PHARMACEUTICAL USE OF HEXAHYDRO-DIBENZO[A,G]QUINOLIZINE COMPOUNDS | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2016-03-09 | — | — | EP | disclosed |
| CN-101292954-A | Anti-cancer medicament sustained-release injection | JINAN SHUAIHUA PHARMACEUTICAL (CN) | 2008-10-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193195-A1 | PHARMACEUTICAL USE OF HEXAHYDRO-DIBENZO[A,G]QUINOLIZINE COMPOUNDS | BPHL, QDPR, NQO2 | XDH 109/4885NUDT1 511/4885POLA1 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.